Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

midostaurin

View Patient Information
A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:N-benzoyl-staurosporine
N-benzoylstaurosporine
US brand name:Rydapt
Code name:CGP 41251
CGP41251
PKC 412
PKC412
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search